Hemab scores $55m Series A
Hemab, a developer of therapeutics for serious underserved bleeding and thrombosis disorders, has raised $55 million in Series A financing.
Hemab, a developer of therapeutics for serious underserved bleeding and thrombosis disorders, has raised $55 million in Series A financing.
Copyright PEI Media
Not for publication, email or dissemination